Resource Summary Report

Generated by SPARC SAWG on Aug 11, 2026

Brilliant Violet 421(TM) anti-human CD19

RRID:AB_11142678
Type: Antibody

Proper Citation

BioLegend Cat# 302234, RRID:AB_11142678

Antibody Information

URL: http://antibodyregistry.org/AB_11142678

Proper Citation: BioLegend Cat# 302234, RRID:AB_11142678

Target Antigen: CD19

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, ICC, IHC-F

Antibody Name: Brilliant Violet 421(TM) anti-human CD19

Description: This monoclonal targets CD19

Target Organism: human

Clone ID: Clone HIB19

Antibody ID: AB_11142678

Vendor: BioLegend

Catalog Number: 302234

Alternative Catalog Numbers: 302233

Record Creation Time: 20250819T223906+0000

Record Last Update: 20250820T025232+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-human CD19.

No alerts have been found for Brilliant Violet 421(TM) anti-human CD19.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 25 mentions in open access literature.

Listed below are recent publications. The full list is available at SPARC SAWG .

Braams M, et al. (2026) ABO: A 3D stroma-supported culture platform enabling full human B-lymphopoiesis for disease modeling and gene therapy development. Cell reports. Medicine, 7(7), 102879.

Bracey NA, et al. (2026) Aging restricts maturation of CXCL13+ T follicular helper cells in human immunity. Cell reports, 45(6), 117423.

Zhou P, et al. (2026) Targeting senescent EGR1+ B cells enhances immunotherapy efficacy in esophageal squamous cell carcinoma. Cell reports. Medicine, 102532.

Fisher H, et al. (2026) Antibody binding geometry and affinity control inhibitory hFc??RIIB receptor signaling. Immunity, 59(7), 2041.

Zeng Z, et al. (2026) Safety and efficacy of low-dose, cord blood-derived CD19 CAR-NK cells with 4-1BB co-stimulation in refractory systemic lupus erythematosus. Med (New York, N.Y.), 101226.

Fujino T, et al. (2026) Development of CAR T cells Targeting a Surface RNA Binding Protein for the Treatment of Acute Leukemias. Cancer discovery.

Ehlers L, et al. (2026) ADA2-deficient cells exhibit increased levels of cell death and metabolic disturbances. Cell death discovery, 12(1).

Montamat-Garcia G, et al. (2026) Human primary antibody response to vaccination follows a partially sequential class-switching program with a checkpoint at IGHG2. Cell reports. Medicine, 7(7), 102848.

Caron DP, et al. (2025) Multimodal hierarchical classification of CITE-seq data delineates immune cell states across lineages and tissues. Cell reports methods, 5(1), 100938.

Pedroza LA, et al. (2025) The Golgi complex governs natural killer cell lytic granule positioning to promote directionality in cytotoxicity. Cell reports, 44(1), 115156.

Lederhofer J, et al. (2024) Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase. Immunity, 57(3), 574.

Wang J, et al. (2024) LILRB1-HLA-G axis defines a checkpoint driving natural killer cell exhaustion in tuberculosis. EMBO molecular medicine, 16(8), 1755.

Takeshita M, et al. (2023) Potent neutralizing broad-spectrum antibody against SARS-CoV-2 generated from dual-antigen-specific B cells from convalescents. iScience, 26(6), 106955.

Long J, et al. (2023) A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment. Cell reports. Medicine, 4(11), 101286.

Nellore A, et al. (2023) A transcriptionally distinct subset of influenza-specific effector memory B cells predicts long-lived antibody responses to vaccination in humans. Immunity, 56(4), 847.

Ruf B, et al. (2023) Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin. Cell, 186(17), 3686.

Zheng H, et al. (2022) Longitudinal analyses reveal distinct immune response landscapes in lung and intestinal tissues from SARS-CoV-2-infected rhesus macaques. Cell reports, 39(8), 110864.

Takeshita M, et al. (2022) Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models. iScience, 25(12), 105596.

Vijayakumar B, et al. (2022) Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease. Immunity, 55(3), 542.

Rossignol ED, et al. (2021) Mining HIV controllers for broad and functional antibodies to recognize and eliminate HIV-infected cells. Cell reports, 35(8), 109167.